Susan Robson
Adult Health · Washington, DCNPI 1558827055
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 32.1% of the total.
Across 44 payments — averaging $27.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$383
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$171
- Madrigal Pharmaceuticals$161
- Veloxis Pharmaceuticals, Inc.$156
- Takeda Pharmaceuticals U.S.A., Inc.$53
- Gilead$43
- plus $225 from 9 others
What the payments were for
- Food & beverage$1,192100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $383 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $171 |
| Madrigal Pharmaceuticals | 6 | $161 |
| Veloxis Pharmaceuticals, Inc. | 6 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Gilead | 2 | $43 |
| AstraZeneca | 1 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| Astellas Pharma US Inc | 1 | $30 |
| Johnson & Johnson | 1 | $28 |
| Intercept Pharmaceuticals, Inc. | 1 | $25 |
| GSK | 1 | $20 |
| Stryker | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Exact Sciences | 1 | $19 |
How this compares
$1,192 in reported general payments places this provider in the 70th percentile of 63 adult health providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 42 | $3,083 |
| Nifedipine ErNifedipine | 33 | $1,874 |
| Lactulose | 17 | $431 |
| Losartan Potassium | 12 | $400 |
| Prednisone | 19 | $150 |
| Tamsulosin Hcl | 13 | $133 |
| Pantoprazole Sodium | 15 | $131 |
| Carvedilol | 21 | $129 |
| Furosemide | 14 | $107 |
| Metoprolol Tartrate | 12 | $90 |
| Famotidine | 11 | $21 |
| Metformin Hcl | 14 | $18 |
Paid to pharmacies, not to this prescriber.
Other adult health in Washington
- Maureen MoriartyWashington$237K
- Monica BaenaWashington$12K
- Barbara WilmarthWashington$10K
- Payal KadakiaWashington$6K
- Aimee ChappellWashington$6K
- Sarah BottomleyWashington$5K
- Rachel BarishWashington$4K
- Jillian ThompsonWashington$3K
- Tracy HolzmanWashington$3K
- Jody BeckWashington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.